Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nowotwory. Journal of Oncology
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Editorial Office Manuscript Submission Reviewers 2022 Best Original Paper Award

open access

Ahead of print
Review paper
Published online: 2023-10-27
View PDF Download PDF file
Get Citation

Wnt pathways in focus – mapping current clinical trials across cancer spectrum

Renata Pacholczak-Madej1, Paulina Frączek2, Klaudia Skrzypek3, Mirosława Püsküllüoğlu4
DOI: 10.5603/njo.97607
Affiliations
  1. Department of Anatomy, Jagiellonian University Medical College, Krakow, Poland
  2. Department of Oncology, University Hospital in Krakow, Poland
  3. Department of Transplantation, Institute of Pediatrics, Jagiellonian University Medical College, Faculty of Medicine, Krakow, Poland
  4. Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Poland

open access

Ahead of print
Review article
Published online: 2023-10-27

Abstract

The Wnt pathway has a pivotal function in tissue development and homeostasis, overseeing cell growth or differentiation. Aberrant Wnt signalling pathways have been associated with the pathogenesis of diverse malignancies, influencing cell proliferation, differentiation, cancer stem cell renewal, tumor microenvironment and thereby significantly impacting tumour development and therapeutic responsiveness. Promisingly, current research underscores the potential therapeutic value of targeting Wnt pathways, particularly the canonical Wnt/β-catenin signalling, in the context of numerous cancer types.

Key constituents of the Wnt pathway, such as the Wnt/receptor, β-catenin degradation or transcription complexes, have been focal points for interventions in preclinical studies. To comprehend potential therapeutic strategies, we conduct an analysis of ongoing clinical trials that specifically aim to target components of the Wnt pathways across a diverse spectrum of cancer types. By scrutinizing these trials, including their respective phases, targeted patient populations, and observed outcomes, this review provides a consolidated overview of the current translational landscape of Wnt-targeted therapies, thus offering a roadmap for future research endeavours.

Abstract

The Wnt pathway has a pivotal function in tissue development and homeostasis, overseeing cell growth or differentiation. Aberrant Wnt signalling pathways have been associated with the pathogenesis of diverse malignancies, influencing cell proliferation, differentiation, cancer stem cell renewal, tumor microenvironment and thereby significantly impacting tumour development and therapeutic responsiveness. Promisingly, current research underscores the potential therapeutic value of targeting Wnt pathways, particularly the canonical Wnt/β-catenin signalling, in the context of numerous cancer types.

Key constituents of the Wnt pathway, such as the Wnt/receptor, β-catenin degradation or transcription complexes, have been focal points for interventions in preclinical studies. To comprehend potential therapeutic strategies, we conduct an analysis of ongoing clinical trials that specifically aim to target components of the Wnt pathways across a diverse spectrum of cancer types. By scrutinizing these trials, including their respective phases, targeted patient populations, and observed outcomes, this review provides a consolidated overview of the current translational landscape of Wnt-targeted therapies, thus offering a roadmap for future research endeavours.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

cancer; clinical trials; Wnt signalling pathways; targeted therapy

About this article
Title

Wnt pathways in focus – mapping current clinical trials across cancer spectrum

Journal

Nowotwory. Journal of Oncology

Issue

Ahead of print

Article type

Review paper

Published online

2023-10-27

Page views

75

Article views/downloads

74

DOI

10.5603/njo.97607

Keywords

cancer
clinical trials
Wnt signalling pathways
targeted therapy

Authors

Renata Pacholczak-Madej
Paulina Frączek
Klaudia Skrzypek
Mirosława Püsküllüoğlu

References (142)
  1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1): 7–33.
    CrossRefPubMed
  2. Ługowska IE. Handbook of Targeted Therapies and Precision Oncology. ESMO Press, Lugano 2022.
  3. Choudhari AS, Mandave PC, Deshpande M, et al. Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice. Front Pharmacol. 2019; 10: 1614.
    CrossRefPubMed
  4. Hughes JP, Rees S, Kalindjian SB, et al. Principles of early drug discovery. Br J Pharmacol. 2011; 162(6): 1239–1249.
    CrossRefPubMed
  5. Berdigaliyev N, Aljofan M. An overview of drug discovery and development. Future Med Chem. 2020; 12(10): 939–947.
    CrossRefPubMed
  6. Kaushik I, Ramachandran S, Prasad S, et al. Drug rechanneling: A novel paradigm for cancer treatment. Semin Cancer Biol. 2021; 68: 279–290.
    CrossRefPubMed
  7. You M, Xie Z, Zhang N, et al. Signaling pathways in cancer metabolism: mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023; 8(1): 196.
    CrossRefPubMed
  8. Lang BJ, Prince TL, Okusha Y, et al. Heat shock proteins in cell signaling and cancer. Biochim Biophys Acta Mol Cell Res. 2022; 1869(3): 119187.
    CrossRefPubMed
  9. Borlongan MC, Wang H. Profiling and targeting cancer stem cell signaling pathways for cancer therapeutics. Front Cell Dev Biol. 2023; 11: 1125174.
    CrossRefPubMed
  10. Yip HY, Papa A. Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. Cells. 2021; 10(3).
    CrossRefPubMed
  11. Wilusz M, Majka M. Role of the Wnt/beta-catenin network in regulating hematopoiesis. Arch Immunol Ther Exp (Warsz). 2008; 56(4): 257–266.
    CrossRefPubMed
  12. Katoh M, Katoh M. WNT signaling and cancer stemness. Essays Biochem. 2022; 66(4): 319–331.
    CrossRefPubMed
  13. Pamarthy S, Kulshrestha A, Katara GK, et al. The curious case of vacuolar ATPase: regulation of signaling pathways. Mol Cancer. 2018; 17(1): 41.
    CrossRefPubMed
  14. Martin-Orozco E, Sanchez-Fernandez A, Ortiz-Parra I, et al. WNT Signaling in Tumors: The Way to Evade Drugs and Immunity. Front Immunol. 2019; 10: 2854.
    CrossRefPubMed
  15. Zhang Ya, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol. 2020; 13(1): 165.
    CrossRefPubMed
  16. Chen Y, Chen Z, Tang Y, et al. The involvement of noncanonical Wnt signaling in cancers. Biomed Pharmacother. 2021; 133: 110946.
    CrossRefPubMed
  17. Xiao Q, Chen Z, Jin X, et al. The many postures of noncanonical Wnt signaling in development and diseases. Biomed Pharmacother. 2017; 93: 359–369.
    CrossRefPubMed
  18. Lepourcelet M, Chen YNP, France DS, et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004; 5(1): 91–102.
    CrossRefPubMed
  19. Hallett RM, Kondratyev MK, Giacomelli AO, et al. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer. PLoS One. 2012; 7(3): e33976.
    CrossRefPubMed
  20. Gonsalves FC, Klein K, Carson BB, et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci U S A. 2011; 108(15): 5954–5963.
    CrossRefPubMed
  21. Bilir B, Kucuk O, Moreno CS. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J Transl Med. 2013; 11: 280.
    CrossRefPubMed
  22. Tian W, Han X, Yan M, et al. Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction. Biochemistry. 2012; 51(2): 724–731.
    CrossRefPubMed
  23. Handeli S, Simon JA. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther. 2008; 7(3): 521–529.
    CrossRefPubMed
  24. Iida J, Dorchak J, Lehman JR, et al. FH535 inhibited migration and growth of breast cancer cells. PLoS One. 2012; 7(9): e44418.
    CrossRefPubMed
  25. Jang GB, Hong IS, Kim RJ, et al. Wnt/β-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells. Cancer Res. 2015; 75(8): 1691–1702.
    CrossRefPubMed
  26. Sulaiman A, McGarry S, Li Li, et al. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states. Mol Oncol. 2018; 12(4): 423–440.
    CrossRefPubMed
  27. Kim HMi, Kim CS, Lee JH, et al. CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells. PLoS One. 2013; 8(4): e60383.
    CrossRefPubMed
  28. Londoño-Joshi AI, Arend RC, Aristizabal L, et al. Effect of niclosamide on basal-like breast cancers. Mol Cancer Ther. 2014; 13(4): 800–811.
    CrossRefPubMed
  29. Lu W, Li Y. Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells. J Cell Biochem. 2014; 115(10): 1799–1807.
    CrossRefPubMed
  30. Lu D, Choi MY, Yu J, et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011; 108(32): 13253–13257.
    CrossRefPubMed
  31. A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands. https://clinicaltrials.gov/ct2/show/NCT01351103 (12.04.2023).
  32. Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations. https://clinicaltrials.gov/ct2/show/NCT02278133 (12.04.2023).
  33. Hayashi M, Baker A, Goldstein SD, et al. Inhibition of porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma. Oncotarget. 2017; 8(45): 78265–78276.
    CrossRefPubMed
  34. Li J, Wu G, Xu Y, et al. Porcupine Inhibitor LGK974 Downregulates the Wnt Signaling Pathway and Inhibits Clear Cell Renal Cell Carcinoma. Biomed Res Int. 2020; 2020: 2527643.
    CrossRefPubMed
  35. A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours. https://clinicaltrials.gov/ct2/show/NCT02521844 (25.11.2022).
  36. CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596). https://clinicaltrials.gov/ct2/show/NCT02675946 (25.11.2022).
  37. Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors. https://clinicaltrials.gov/ct2/show/NCT03507998 (25.11.2022).
  38. Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies. https://clinicaltrials.gov/ct2/show/NCT03447470 (25.11.2022).
  39. A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2). https://clinicaltrials.gov/ct2/show/NCT04907851 (25.11.2022).
  40. A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC). https://clinicaltrials.gov/ct2/show/NCT04907539 (25.11.2022).
  41. Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT03901950 (25.11.2022).
  42. Smith D, Rosen L, Chugh R, et al. First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors. Journal of Clinical Oncology. 2013; 31(15_suppl): 2540–2540.
    CrossRef
  43. Davis SL, Cardin DB, Shahda S, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2020; 38(3): 821–830.
    CrossRefPubMed
  44. A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer. https://clinicaltrials.gov/ct2/show/NCT02005315 (25.11.2022).
  45. A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC. https://clinicaltrials.gov/ct2/show/NCT01957007 (25.11.2022).
  46. Diamond JR, Becerra C, Richards D, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020; 184(1): 53–62.
    CrossRefPubMed
  47. Jimeno A, Gordon M, Chugh R, et al. A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017; 23(24): 7490–7497.
    CrossRefPubMed
  48. A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT01608867 (25.11.2022).
  49. Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer. https://clinicaltrials.gov/ct2/show/NCT02069145 (25.11.2022).
  50. Moore KN, Gunderson CC, Sabbatini P, et al. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019; 154(2): 294–301.
    CrossRefPubMed
  51. Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer. https://clinicaltrials.gov/ct2/show/NCT02092363 (25.11.2022).
  52. Dotan E, Cardin DB, Lenz HJ, et al. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Clin Cancer Res. 2020; 26(20): 5348–5357.
    CrossRefPubMed
  53. Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma. https://clinicaltrials.gov/ct2/show/NCT04176016 (25.11.2022).
  54. Arqués O, Chicote I, Puig I, et al. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016; 22(3): 644–656.
    CrossRefPubMed
  55. Bao R, Christova T, Song S, et al. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. PLoS One. 2012; 7(11): e48670.
    CrossRefPubMed
  56. El-Khoueiry A, Ning Y, Yang D, et al. A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. J Clin Oncol. 2013; 31(15_suppl): 2501–2501.
    CrossRef
  57. Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT01302405 (25.11.2022).
  58. Ko A, Chiorean E, Kwak E, et al. Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. J Clin Oncol. 2016; 34(15_suppl): e15721–e15721.
    CrossRef
  59. Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma. https://clinicaltrials.gov/ct2/show/NCT01764477 (25.11.2022).
  60. Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies. https://clinicaltrials.gov/ct2/show/NCT01606579 (25.11.2022).
  61. Lee JH, Faderl S, Pagel JM, et al. Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2020; 4(9): 2032–2043.
    CrossRefPubMed
  62. Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients. https://clinicaltrials.gov/ct2/show/NCT01398462 (25.11.2022).
  63. Yoon SS, Manasanch E, Min C, et al. Novel phase 1a/1b dose-finding study design of CWP232291 (CWP291) in relapsed or refractory myeloma (MM). J Clin Oncol. 2017; 35(15_suppl): TPS8058–TPS8058.
    CrossRef
  64. Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients. https://clinicaltrials.gov/ct2/show/NCT02426723 (25.11.2022).
  65. Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients. https://clinicaltrials.gov/ct2/show/NCT03055286 (25.11.2022).
  66. Klempner SJ, Bendell JC, Villaflor VM, et al. Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. Mol Cancer Ther. 2021; 20(11): 2240–2249.
    CrossRefPubMed
  67. A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab. https://clinicaltrials.gov/ct2/show/NCT02013154 (25.11.2022).
  68. Goyal L, Sirard C, Schrag M, et al. Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. Clin Cancer Res. 2020; 26(23): 6158–6167.
    CrossRefPubMed
  69. Goyal L, Sirard C, Schrag M, et al. Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. Clin Cancer Res. 2020; 26(23): 6158–6167.
    CrossRefPubMed
  70. Wise DR, Schneider JA, Armenia J, et al. International SU2C/PCF Prostate Cancer Dream Team. Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2020; 4.
    CrossRefPubMed
  71. A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1. https://clinicaltrials.gov/ct2/show/NCT03837353 (25.11.2022).
  72. DKN-01 Inhibition in Advanced Liver Cancer. https://clinicaltrials.gov/ct2/show/NCT03645980 (25.11.2022).
  73. Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC). https://clinicaltrials.gov/ct2/show/NCT04057365 (25.11.2022).
  74. A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma. https://clinicaltrials.gov/ct2/show/NCT03395080 (25.11.2022).
  75. A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer. https://clinicaltrials.gov/ct2/show/NCT04363801 (25.11.2022).
  76. Edenfield W, Richards D, Vukelja S, et al. A phase 1 study evaluating the safety and efficacy of DKN-01, an investigational monoclonal antibody (Mab) in patients (pts) with advanced non-small cell lung cancer. J Clin Oncol. 2014; 32(15_suppl): 8068–8068.
    CrossRef
  77. A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT01457417 (25.11.2022).
  78. WaKING: Wnt and checKpoint INhibition in Gastric Cancer. https://clinicaltrials.gov/ct2/show/NCT04166721 (25.11.2022).
  79. Soerensen P, Andersson T, Buhl U, et al. Phase I dose-escalating study to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of Foxy-5 in patients with metastatic breast, colorectal, or prostate cancer. J Clin Oncol. 2014; 32(15_suppl): TPS1140–TPS1140.
    CrossRef
  80. Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer. https://clinicaltrials.gov/ct2/show/NCT02020291 (25.11.2022).
  81. Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer. https://clinicaltrials.gov/ct2/show/NCT03883802 (25.11.2022).
  82. Study of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer. https://clinicaltrials.gov/ct2/show/NCT05156905 (25.11.2022).
  83. Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961. https://clinicaltrials.gov/ct2/show/NCT02860676 (25.11.2022).
  84. UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia. https://clinicaltrials.gov/ct2/show/NCT02222688 (25.11.2022).
  85. Lee H, Choi M, Siddiqi T, et al. Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). J Clin Oncol. 2021; 39(15_suppl): 7556–7556.
    CrossRef
  86. A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies. https://clinicaltrials.gov/ct2/show/NCT03088878 (25.11.2022).
  87. Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax. https://clinicaltrials.gov/ct2/show/NCT04501939 (25.11.2022).
  88. Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer. https://clinicaltrials.gov/ct2/show/NCT02776917 (25.11.2022).
  89. Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer. https://clinicaltrials.gov/ct2/show/NCT02413853 (25.11.2022).
  90. Ko A, Chiorean E, Kwak E, et al. Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. J Clin Oncol. 2016; 34(15_suppl): e15721–e15721.
    CrossRef
  91. Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma. https://clinicaltrials.gov/ct2/show/NCT01764477 (25.11.2022).
  92. Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies. https://clinicaltrials.gov/ct2/show/NCT01606579 (25.11.2022).
  93. El-Khoueiry A, Ning Y, Yang D, et al. A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. J Clin Oncol. 2013; 31(15_suppl): 2501–2501.
    CrossRef
  94. Damelin M, Bankovich A, Bernstein J, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017; 9(372).
    CrossRefPubMed
  95. Katoh M. Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis. Ann Transl Med. 2017; 5(23): 462.
    CrossRefPubMed
  96. An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer. https://clinicaltrials.gov/ct2/show/NCT03243331 (25.11.2022).
  97. Radovich M, Solzak JP, Hancock BA, et al. Abstract OT3-06-02: An initial safety study of gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer. Cancer Research. 2019; 79(4_Supplement): OT3-06-02-OT3-06–02.
    CrossRef
  98. An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer. https://clinicaltrials.gov/ct2/show/NCT04189614?term=Cofetuzumab+pelidotin&draw=2&rank=1 (25.11.2022).
  99. Maitland ML, Sachdev JC, Sharma MR, et al. First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clin Cancer Res. 2021; 27(16): 4511–4520.
    CrossRefPubMed
  100. A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT02222922 (25.11.2022).
  101. Sekulic A, Migden MR, Basset-Seguin N, et al. ERIVANCE BCC Investigators. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017; 17(1): 332.
    CrossRefPubMed
  102. CHMP. VISMODEGIB- ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. https://www.ema.europa.eu/en/documents/product-information/erivedge-epar-product-information_en.pdf.
  103. Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020; 182(6): 1369–1378.
    CrossRefPubMed
  104. CHMP. SONIDEGIB- ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. https://www.ema.europa.eu/en/documents/product-information/odomzo-epar-product-information_en.pdf.
  105. Wagner AJ, Messersmith WA, Shaik MN, et al. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015; 21(5): 1044–1051.
    CrossRefPubMed
  106. A Study Of PF-04449913 Administered Alone In Select Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT01286467 (25.05.2022).
  107. Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma. https://clinicaltrials.gov/ct2/show/NCT03466450 (25.05.2022).
  108. Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas. https://clinicaltrials.gov/ct2/show/NCT02828111 (25.05.2022).
  109. Richards D, Stephenson J, Wolpin B, et al. A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer. Journal of Clinical Oncology. 2012; 30(4_suppl): 213–213.
    CrossRef
  110. A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer. https://clinicaltrials.gov/ct2/show/NCT01130142 (25.05.2022).
  111. Ko AH, LoConte N, Tempero MA, et al. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016; 45(3): 370–375.
    CrossRefPubMed
  112. FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma. https://clinicaltrials.gov/ct2/show/NCT01383538 (25.05.2022).
  113. Jimeno A, Weiss GJ, Miller WH, et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013; 19(10): 2766–2774.
    CrossRefPubMed
  114. A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies. https://clinicaltrials.gov/ct2/show/NCT00761696 (25.11.2022).
  115. Bowles DW, Keysar SB, Eagles JR, et al. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2016; 53: 74–79.
    CrossRefPubMed
  116. Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer. https://clinicaltrials.gov/ct2/show/NCT01255800 (25.11.2022).
  117. A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma. https://clinicaltrials.gov/ct2/show/NCT01310816 (25.11.2022).
  118. A Study of LY2940680 in Japanese Participants With Advanced Cancers. https://clinicaltrials.gov/ct2/show/NCT01919398 (25.11.2022).
  119. A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations. https://www.clinicaltrials.gov/ct2/show/NCT05199584 (25.11.2022).
  120. A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT02784795 (25.11.2022).
  121. Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer. https://clinicaltrials.gov/ct2/show/NCT02530437 (25.11.2022).
  122. Moroni M, Pirovano M, Brugnatelli S, et al. Lycopene minimizes skin toxicity and oxidative stress in patients treated with panitumumab-containing therapy for metastatic colorectal cancer. J Funct Foods. 2021; 83: 104533.
    CrossRef
  123. Kim M, Kim SH, Lim JW, et al. Lycopene induces apoptosis by inhibiting nuclear translocation of β-catenin in gastric cancer cells. J Physiol Pharmacol. 2019; 70(4).
    CrossRefPubMed
  124. Preet R, Mohapatra P, Das D, et al. Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC. Carcinogenesis. 2013; 34(2): 277–286.
    CrossRefPubMed
  125. Hamoya T, Fujii G, Iizumi Y, et al. Artesunate inhibits intestinal tumorigenesis through inhibiting wnt signaling. Carcinogenesis. 2021; 42(1): 148–158.
    CrossRefPubMed
  126. A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer. https://clinicaltrials.gov/ct2/show/NCT02633098 (25.11.2022).
  127. Deeken JF, Wang H, Hartley M, et al. A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2018; 81(3): 587–596.
    CrossRefPubMed
  128. Phase I Study of Intravenous Artesunate for Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT02353026 (25.11.2022).
  129. von Hagens C, Walter-Sack I, Goeckenjan M, et al. Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). Breast Cancer Res Treat. 2017; 164(2): 359–369.
    CrossRefPubMed
  130. Study of Artesunate in Metastatic Breast Cancer. https://clinicaltrials.gov/ct2/show/NCT00764036 (25.11.2022).
  131. Holcombe R, Holcombe R. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Management and Research. 2009: 25.
    CrossRef
  132. Resveratrol for Patients With Colon Cancer. https://clinicaltrials.gov/ct2/show/NCT00256334?term=NCT00256334&draw=2&rank=1 (25.11.2022).
  133. Fu Y, Chang H, Peng X, et al. Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/β-catenin signaling pathway. PLoS One. 2014; 9(7): e102535.
    CrossRefPubMed
  134. Dai H, Deng HB, Wang YH, et al. Resveratrol inhibits the growth of gastric cancer via the Wnt/β-catenin pathway. Oncol Lett. 2018; 16(2): 1579–1583.
    CrossRefPubMed
  135. Reyes-Farias M, Carrasco-Pozo C. The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism. Int J Mol Sci. 2019; 20(13).
    CrossRefPubMed
  136. Khorsandi L, Orazizadeh M, Niazvand F, et al. Quercetin induces apoptosis and necroptosis in MCF-7 breast cancer cells. Bratisl Lek Listy. 2017; 118(2): 123–128.
    CrossRefPubMed
  137. Niazvand F, Orazizadeh M, Khorsandi L, et al. Effects of Quercetin-Loaded Nanoparticles on MCF-7 Human Breast Cancer Cells. Medicina (Kaunas). 2019; 55(4).
    CrossRefPubMed
  138. Zhao W, Jia L, Kuai X, et al. The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated β-catenin in gastric cancer. Cancer Med. 2019; 8(3): 1135–1147.
    CrossRefPubMed
  139. Rahimi Kalateh Shah Mohammad G, Ghahremanloo A, Soltani A, et al. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment. J Cell Physiol. 2020; 235(7-8): 5449–5460.
    CrossRefPubMed
  140. Jiang H, Zhang Z, Yu Y, et al. Drug Discovery of DKK1 Inhibitors. Front Pharmacol. 2022; 13: 847387.
    CrossRefPubMed
  141. Yamada K, Hori Y, Inoue S, et al. E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling. Cancer Res. 2021; 81(4): 1052–1062.
    CrossRefPubMed
  142. Moroni M, Pirovano M, Brugnatelli S, et al. Lycopene minimizes skin toxicity and oxidative stress in patients treated with panitumumab-containing therapy for metastatic colorectal cancer. J Funct Foods. 2021; 83: 104533.
    CrossRef

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl